[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Venkatarajan S, LeLeux TM, Yang D, Rosen T, Orengo I: Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil. Dermatol Online J; 2010;16(12):10
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil.
  • With a 7.5 percent risk of malignancy, PM should be treated to prevent transformation into squamous cell carcinoma, Bowen disease, or basal cell carcinoma.
  • Multiple treatment options are available, however, there is not one universally effective treatment.
  • We describe the successful treatment of porokeratosis of Mibelli of the left calf in an 83-year-old man with topical 5 percent imiquimod and topical 5 percent 5-fluorouracil.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antimetabolites / therapeutic use. Fluorouracil / therapeutic use. Immunologic Factors / therapeutic use. Porokeratosis / drug therapy. Precancerous Conditions / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged, 80 and over. Carcinoma, Basal Cell / complications. Humans. Leg. Male. Remission Induction. Skin Neoplasms / complications. Skin Neoplasms / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199636.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antimetabolites; 0 / Immunologic Factors; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Mahieu-Renard L, Richard MA, Dales JP, Buscaylet S, Lagrassa S, Grob JJ: [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine]. Ann Dermatol Venereol; 2005 Apr;132(4):346-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
  • [Transliterated title] Traitement de métastases cutanées d'un carcinome épidermoïde de la jambe par applications de miltéfosine.
  • INTRODUCTION: Miltefosine (Hexadecylphosphocholine) is a chemotherapy, which when applied locally, has demonstrated efficacy in the treatment of cutaneous metastases of breast cancer.
  • CASE REPORT: A 79 year-old woman developed recurrent in transit cutaneous metastases of a squamous cell carcinoma on her left leg.
  • Tolerance was excellent and the patient remained disease-free 24 months after the end of the treatment.
  • DISCUSSION: Miltefosine, which might prove to be a simple and effective alternative for the usually heavy treatments proposed, warrants further assessment in this context.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Phosphorylcholine / analogs & derivatives. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary
  • [MeSH-minor] Administration, Topical. Aged. Female. Humans. Leg

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886562.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 107-73-3 / Phosphorylcholine; 53EY29W7EC / miltefosine
  •  go-up   go-down


3. Asuquo ME, Udosen AM, Ikpeme IA, Ngim NE, Otei OO, Ebughe G, Bassey EE: Cutaneous squamous cell carcinoma in Calabar, southern Nigeria. Clin Exp Dermatol; 2009 Dec;34(8):870-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma in Calabar, southern Nigeria.
  • BACKGROUND: Several studies have shown that in Africa squamous cell carcinoma (SCC) is commoner than other skin malignancies.
  • METHODS: All patients with histological diagnosis of SCC presenting to the University of Calabar Teaching Hospital during the period January 2005 to December 2006 were evaluated.
  • There were six patients (60%) with Marjolin's ulcer (MU) of the leg, with a male:female ratio of 5:1 and a latency period of 14.7 years, with trauma as the leading cause of injury.
  • All 10 patients had delayed hospital admission, after poor results with topical herbal treatment.
  • After hospital treatment, the results were satisfactory in three patients (two with MU and the male albino patient).
  • The other seven patients had generally poor results from treatment, which comprised various combinations of excision, adjuvant chemotherapy and radiation.
  • CONCLUSION: Ignorance and sociocultural factors were underlying issues in delaying treatment.
  • Education highlighting the risk associated with chronic wounds and albinism, and the need for prevention, prompt treatment and proper surgical management, would improve prognosis with a reduction in the healthcare cost of this problem.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Albinism / complications. Female. Health Knowledge, Attitudes, Practice. Humans. Male. Middle Aged. Nigeria / epidemiology. Prevalence. Prognosis. Risk Factors. Skin Pigmentation. Young Adult


Advertisement
4. Goh MS: Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol; 2006 Aug;47(3):186-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream.
  • Squamous cell carcinoma in situ has the potential to progress to invasive squamous cell carcinoma.
  • This report presents two cases of punch biopsy-proven squamous cell carcinoma in situ, treated with once-daily application of 5% imiquimod cream for 6 weeks.
  • Both patients developed moderate local inflammatory reactions during treatment.
  • The first patient demonstrated clinical clearance of the scalp lesion after treatment.
  • Histology was consistent with recurrent squamous cell carcinoma.
  • Five months following excision of the recurrent tumour, he presented with metastatic squamous cell carcinoma to a cervical lymph node.
  • The second patient had low-grade chronic lymphocytic leukaemia and presented with squamous cell carcinoma in situ of the leg that failed to clear clinically after treatment with imiquimod.
  • He presented 4 months later with a focus of invasive squamous cell carcinoma within the lesion.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasms, Second Primary / diagnosis. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Disease Progression. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / surgery. Humans. Leg. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Scalp. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867000.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


5. Smith KJ, Germain M, Skelton H: Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg; 2001 Jun;27(6):561-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy.
  • BACKGROUND: Depending upon the patient's age at transplant, skin type, sun exposure, and the need for immunosuppressive therapy to prevent rejection, there is escalation in the development of cutaneous malignancies in organ transplant patients a number of years after transplantation.
  • OBJECTIVE: To determine if combined therapy with 5% 5-fluorouracil and 5% imiquimod may be useful in the treatment of squamous cell carcinoma in situ.
  • METHODS: We present five renal transplant patients, all more than 10 years posttransplantation, three with insulin-dependent diabetes, who developed multiple areas of squamous cell carcinoma (SCC) in situ.
  • All these patients were on chronic immunosuppressive chemotherapy to prevent rejection, but were otherwise doing well.
  • RESULTS: We treated these five patients with a combination of a local immune therapy, imiquimod cream, and a topical chemotherapeutic agent, 5% 5-fluorouracil (5-FU), with clearing of the areas of SCC in situ.
  • In addition, there is evidence that cytokines induced by imiquimod may improve the therapeutic efficacy of topical 5% 5-FU in the treatment of SCC in situ.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Fluorouracil / therapeutic use. Immunosuppressive Agents / therapeutic use. Kidney Transplantation. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Leg. Male. Middle Aged. Pilot Projects. Survivors. Treatment Outcome


6. Ardabili M, Gambichler T, Rotterdam S, Altmeyer P, Hoffmann K, Stücker M: Metastatic cutaneous squamous cell carcinoma arising from a previous area of chronic hypertrophic lichen planus. Dermatol Online J; 2003 Feb;9(1):10
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic cutaneous squamous cell carcinoma arising from a previous area of chronic hypertrophic lichen planus.
  • The tumor gradually developed within previous areas of histologically proven hypertrophic lichen planus that had existed for about 10 years.
  • However, the current histological examination of the excised tumor revealed highly differentiated squamous cell carcinoma with a depth of tumor invasion of 10 mm.
  • At that time, neither sentinel lymph node biopsy nor further imaging diagnostics revealed evidence for metastatic spreading.
  • Initial chemotherapy and inguinal lymph node dissection were unable to stop the spread of the tumor.
  • One year later, parailiacal lymph node metastases were detected by computed tomography.
  • Further cycles of chemotherapy resulted in significant reduction of the parailiacal tumor masses.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Cell Transformation, Neoplastic / pathology. Lichen Planus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chronic Disease. Cisplatin / administration & dosage. Groin. Humans. Leg. Lymphatic Metastasis. Male. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12639468.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Mann M, Berk DR, Petersen J: Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol; 2008 Jul;7(7):685-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities.
  • BACKGROUND: Managing patients with diffuse squamous cell carcinoma (SCC) and actinic damage on their extremities is challenging because SCCs may be ill-defined, confluent, and only amenable to radical surgery.
  • Before chemowraps were applied, biopsies and clinical lymph node examinations were performed to confirm the diagnosis of SCC.
  • Patients were informed that chemowraps represent an off-label use of 5-FU to reduce actinic keratoses as an adjuvant to definitive surgery for SCCs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bandages. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Chemotherapy, Adjuvant. Female. Humans. Keratosis / drug therapy. Leg

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664163.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Nouri K, O'Connell C, Rivas MP: Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. J Drugs Dermatol; 2003 Dec;2(6):669-73
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.
  • Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts.
  • Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas.
  • There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod.
  • We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream.
  • Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma.
  • Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ.
  • It also seems to be an alternative treatment for some cases of squamous cell carcinoma.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Bowen's Disease / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Female. Humans. Leg. Male. Nose. Shoulder. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14711149.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


9. Bevan-Thomas R, Slaton JW, Pettaway CA: Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol; 2002 Apr;167(4):1638-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience.
  • PURPOSE: Inguinal lymphadenectomy can be curative in patients with small volume inguinal metastases and those with more significant adenopathy responding to combination chemotherapy.
  • We reviewed our recent experience with lymphadenectomy in patients with invasive penile cancer who were judged to require inguinal staging and therapeutic procedures to assess the incidence and magnitude of complications caused by this procedure, especially in those with no palpable adenopathy (prophylactic group).
  • The indications for dissection were prophylactic in 66 (62%) patients in whom a superficial dissection alone was completed on the ipsilateral side, therapeutic in 28 (26%) in whom superficial, deep and ipsilateral pelvic dissections were performed, and palliative in 12 (11%) undergoing extensive resection of inguinal and abdominal wall tissue after chemotherapy.
  • Minor postoperative complications included those requiring local wound débridement in the clinic, mild to moderate leg edema, seroma formation not requiring aspiration and minimal skin edge necrosis requiring no therapy.
  • Major complications included severe leg edema interfering with ambulation, skin flap necrosis requiring a skin graft, rehospitalization, deep venous thrombosis, death, or reexploration or other invasive procedures performed in the operating room.
  • Prophylactic and therapeutic dissections were associated with a lower incidence of complications compared with palliative dissections (p = 0.017 to 0.049).
  • When compared with 3 prior series, the incidence of skin edge necrosis in our series was significantly lower (8% versus 45% to 62%, p <0.0001).
  • Similarly the morbidity of therapeutic lymphadenectomy appeared acceptable, considering the potential therapeutic benefit.
  • Optimal candidates are those having a significant response to systemic chemotherapy whose groins are grossly uninfected.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision / adverse effects. Penile Neoplasms / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11912379.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Nikkels AF, Thirion L, Quatresooz P, Piérard GE: Photodynamic therapy for cutaneous verrucous carcinoma. J Am Acad Dermatol; 2007 Sep;57(3):516-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for cutaneous verrucous carcinoma.
  • Cutaneous verrucous carcinoma is a low-grade and well-differentiated variant of squamous cell carcinoma.
  • Photodynamic therapy relies on the selective intratumoral cell accumulation and photoactivation of a photosensitizer, leading to the generation of phototoxic compounds responsible for necrosis and apoptosis of the target cells.
  • An 82-year-old man presenting with a large long-standing verrucous carcinoma on the leg was treated successfully by 6 photodynamic therapy sessions administered at weekly intervals using methyl-aminolevulinate and 57-J/cm(2) irradiations at 634-nm wavelength.
  • The use of methyl-aminolevulinate-photodynamic therapy for treating cutaneous verrucous carcinoma had not been reported so far.
  • It may represent a convenient therapeutic alternative in this setting.
  • [MeSH-major] Carcinoma, Verrucous / drug therapy. Leg Dermatoses / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Chronic Disease. Drug Administration Schedule. Humans. Male. Photosensitizing Agents / administration & dosage. Photosensitizing Agents / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434646.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


11. Wang CH, Nien HC, Hou MF, Chen GS, Cheng ST: Sentinel lymphadenectomy for circumscribed cutaneous T-cell lymphoma. Dermatol Surg; 2004 Jun;30(6):952-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymphadenectomy for circumscribed cutaneous T-cell lymphoma.
  • BACKGROUND: Sentinel lymphadenectomy has been associated with fewer complications in evaluating regional lymph nodes from melanoma or squamous cell carcinoma.
  • This is the first report demonstrating sentinel lymphadenectomy may be useful on primary cutaneous anaplastic large-cell lymphoma.
  • OBJECTIVE: The objective was to assess the efficacy of sentinel lymphadenectomy on primary cutaneous anaplastic large-cell lymphoma.
  • METHODS: Sentinel lymphadenectomy was performed on a patient with a localized CD30+ primary cutaneous anaplastic large-cell lymphoma.
  • Total excision was performed without systemic chemotherapy or immunotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Leg. Lymphatic Metastasis. Middle Aged. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15171780.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Voutsadakis IA, Bruckner HW: Eccrine sweat gland carcinoma: a case report and review of diagnosis and treatment. Conn Med; 2000 May;64(5):263-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine sweat gland carcinoma: a case report and review of diagnosis and treatment.
  • Carcinomas of the skin appendices are rare neoplasms but for prognostic reasons it is important to differentiate them from the indolent squamous and basal cell carcinomas, as their behavior is more aggressive.
  • We report on a case of eccrine sweat gland carcinoma that displayed all the typical features of those neoplasms.
  • The patient sought medical attention after a lesion in his foot, already present for four years, began to enlarge and developed satellite lesions.
  • The pathological diagnosis was made only after the lesion was initially misdiagnosed as basal cell carcinoma of the skin.
  • Multiple chemotherapeutic regimens and radiation therapy were administered with only temporary benefit.
  • The patient developed distant metastatic disease but survived with metastases for three years.
  • He died nine years after the initial lesion developed in his foot and five years after the diagnosis.
  • The diagnosis of sweat gland carcinomas can be facilitated by histochemical stains.
  • In contrast to squamous and basal cell carcinomas of the skin, these are generally positive for the carcinoembryonic antigen (CEA).
  • Once metastatic, these neoplasms are only infrequently, and usually briefly, responsive to either chemotherapy or radiotherapy and new treatments are urgently needed.
  • Early recognition of the entity may allow more timely treatment.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / pathology. Sweat Gland Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Fatal Outcome. Humans. Leg. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Neoplasms / diagnosis. Spinal Neoplasms / secondary. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10860232.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 31
  •  go-up   go-down


13. Iacobellis C, Olmeda A: The Ilizarov method in the treatment of malignant neoplasms of the tibia. Chir Organi Mov; 2004 Jul-Aug;89(3):245-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ilizarov method in the treatment of malignant neoplasms of the tibia.
  • A total of 3 malignant neoplasms of the tibia are presented: 1 is a mesenchymal chondrosarcoma of the tibial pylon (male aged 14 years), and 2 are cases of squamous skin carcinoma of the leg with tibial infiltration (1 male and 1 female aged 32 and 64 years, respectively).
  • The regenerate obtained was slowly corticalized in the first patient, submitted to various cycles of chemotherapy during the course of distraction.
  • In the other two cases, which were not treated by chemotherapy during distraction, corticalization occurred over a shorter amount of time.
  • [MeSH-major] Bone Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Chondrosarcoma, Mesenchymal / surgery. Ilizarov Technique. Tibia
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arthrodesis. Bone Transplantation. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Osteogenesis, Distraction. Osteotomy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Time Factors. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751591.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P: [Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation]. Rev Med Interne; 2000 Jan;21(1):30-4
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Hydroxyurea is a treatment of myeloproliferative syndromes.
  • All but one had cutaneous side-effects, including dryness (n = 16), moderate alopecia (n = 2), increased skin pigmentation (n = 5), melanonychia, single (n = 1) or multiple (n = 7), cutaneous atrophy (n = 4), leg ulcers (n = 8), plantar keratoderma (n = 3), pseudodermatomyositis (n = 1), lichen planus-like eruption on the dorsum of the hands (n = 2), actinic keratosis (n = 8), squamous cell carcinomas (n = 2), and mouth ulcerations (n = 1).
  • They are usually benign, but some of them, in particular leg ulcers and squamous cell carcinomas, lead to modification of the treatment (39% of studied patients).

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10685452.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


15. Hoff NP, Akanay-Diesel S, Pippirs U, Schulte KW, Hanneken S: [Cutaneous side effects of hydroxyurea treatment for polycythemia vera]. Hautarzt; 2009 Oct;60(10):783-7
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous side effects of hydroxyurea treatment for polycythemia vera].
  • [Transliterated title] Kutane Nebenwirkungen einer Hydroxyurea-Therapie bei Polycythaemia vera.
  • A 68-year-old women with polycythemia vera was treated with hydroxyurea for 8 years and developed painful ulcers on her lower legs, multiple hypertrophic actinic keratoses and a squamous cell carcinoma.
  • After discontinuing hydroxyurea therapy the leg ulcers resolved within 8 weeks.
  • The hypertrophic actinic keratoses and squamous cell carcinoma were treated with cryotherapy and excision, respectively.
  • Hydroxyurea induces a variety of cutaneous side effects such as painful leg ulcers and squamous cell carcinomas.
  • Given the wide variety of adverse cutaneous side effects associated with long-term hydroxyurea therapy, the first step in management is to insure that physicians and patients are aware of the specific risks of this treatment.
  • Patients under hydroxyurea therapy should be monitored closely by dermatologists to early detect and treat the cutaneous side effects.
  • [MeSH-major] Carcinoma, Squamous Cell / chemically induced. Drug Eruptions / diagnosis. Hydroxyurea / adverse effects. Leg Ulcer / chemically induced. Leg Ulcer / diagnosis. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Antisickling Agents / adverse effects. Antisickling Agents / therapeutic use. Female. Humans. Polycythemia Vera / complications. Polycythemia Vera / drug therapy

  • Genetic Alliance. consumer health - Polycythemia vera.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Dermatol. 1998 Mar;8(2):114-5 [9649662.001]
  • [Cites] Hematol Oncol. 2009 Jun;27 Suppl 1:11-3 [19468982.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 2):372-4 [9703157.001]
  • [Cites] Int J Dermatol. 2006 Feb;45(2):158-60 [16445510.001]
  • [Cites] Clin Lab Haematol. 2000 Aug;22(4):229-32 [11012636.001]
  • [Cites] J Am Acad Dermatol. 2004 Aug;51(2):293-300 [15280852.001]
  • [Cites] Pharmacol Ther. 1985;31(3):165-76 [3939629.001]
  • [Cites] Ann Dermatol Venereol. 1995;122(1-2):16-8 [7668775.001]
  • [Cites] J Am Acad Dermatol. 1991 Sep;25(3):518-24 [1918491.001]
  • (PMID = 19756436.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antisickling Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


16. Chen K, Shumack S: Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream. Clin Exp Dermatol; 2003 Nov;28 Suppl 1:10-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream.
  • Bowen's disease (BD; intraepithelial squamous cell carcinoma) is a challenging condition to treat because lesions, which can be multiple, are often located at sites that heal poorly, such as the shin.
  • Two elderly female patients with Bowen's disease of the lower leg are presented.
  • Imiquimod 5% cream was applied in a cycle of three times weekly for 3 weeks followed by a 4-week rest period.
  • The treatment was successful after a second cycle of therapy, with both cases clinically clear at 2- and 3-month follow-up visits.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Bowen's Disease / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Middle Aged. Ointments. Treatment Outcome

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616804.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


17. Bula P, Bula-Sternberg J, Wollina U, Haroske G, Bonnaire F: [Marjolin's ulcer: malignant transformation of a crural ulcer due to posttraumatic chronic osteomyelitis]. Unfallchirurg; 2010 Feb;113(2):149-54
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of an 81-year-old female patient who developed a squamous cell carcinoma in a long-lasting therapy-resistant crural ulcer of the lower leg due to posttraumatic chronic osteomyelitis.
  • Eventually the lower leg had to be amputated because of massive destruction of soft tissue and the tibia bone.
  • [MeSH-major] Amputation. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Transformation, Neoplastic / pathology. Leg Injuries / pathology. Leg Injuries / surgery. Leg Ulcer / pathology. Leg Ulcer / surgery. Osteomyelitis / pathology. Osteomyelitis / surgery. Pseudomonas Infections / pathology. Pseudomonas Infections / surgery. Pseudomonas aeruginosa. Skin Ulcer / pathology. Tibia / surgery. Wounds, Penetrating / pathology. Wounds, Penetrating / surgery
  • [MeSH-minor] Aged, 80 and over. Artificial Limbs. Chronic Disease. Disease Progression. Drug Resistance, Bacterial. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Skin / pathology

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1999 May;(362):181-9 [10335297.001]
  • [Cites] J South Orthop Assoc. 1999 Fall;8(3):181-7 [12132863.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jan;63(1):62-4 [9064114.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Jul;6(7):569-72 [18248496.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):571-4 [7577586.001]
  • [Cites] Acta Orthop Belg. 1993;59(4):327-32 [8116362.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Aug;21(7):935-41 [17659003.001]
  • [Cites] Adv Dermatol. 1987;2:19-46 [3079255.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Med J Aust. 1996 Jun 17;164(12):718-20 [8668077.001]
  • [Cites] South Med J. 2005 Oct;98(10):1053 [16295826.001]
  • [Cites] Dermatol Online J. 2007 May 01;13(2):27 [17498446.001]
  • [Cites] Indian J Cancer. 1996 Sep;33(3):139-44 [9055488.001]
  • [Cites] J Burn Care Rehabil. 1990 Sep-Oct;11(5):460-9 [2246317.001]
  • [Cites] Int J Dermatol. 1991 Jan;30(1):58-61 [1993569.001]
  • [Cites] Int Orthop. 2001;25(6):389-91 [11820449.001]
  • [Cites] J Foot Surg. 1981 Fall;20(3):136-41 [7276451.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jan;72(1):12-8 [2295659.001]
  • [Cites] J Clin Pathol. 1963 Nov;16:573-80 [14076377.001]
  • [Cites] Ann Dermatol Venereol. 1993;120(10):675-8 [8161096.001]
  • [Cites] Orthop Rev. 1991 Jul;20(7):625-8 [1945509.001]
  • [Cites] Ann Surg. 1981 May;193(5):598-605 [7235765.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Feb;20(2):141-3 [8113507.001]
  • [Cites] J Mal Vasc. 2001 Apr;26(2):85-91 [11319413.001]
  • [Cites] Clin Orthop Relat Res. 1985 Sep;(198):264-7 [4028559.001]
  • [Cites] Dermatol Surg. 1996 Dec;22(12):1015-8 [9078313.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2007 Feb;93(1):63-71 [17389826.001]
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):331-7 [11465774.001]
  • [Cites] Arch Phys Med Rehabil. 1986 Nov;67(11):831-3 [3778183.001]
  • (PMID = 19859679.001).
  • [ISSN] 1433-044X
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Kuan YZ, Hsu HC, Kuo TT, Huang YH, Ho HC: Multiple verrucous carcinomas treated with acitretin. J Am Acad Dermatol; 2007 Feb;56(2 Suppl):S29-32
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous verrucous carcinoma is a rare variant of low-grade squamous cell carcinoma.
  • It usually involves distal extremities and is often misdiagnosed as giant warts.
  • Immunohistochemical study with proliferating cell nuclear antigen revealed positive staining of the basal and suprabasal layers.
  • [MeSH-major] Acitretin / therapeutic use. Carcinoma, Verrucous / drug therapy. Keratolytic Agents / therapeutic use. Leg. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Immunohistochemistry / methods. Male. Proliferating Cell Nuclear Antigen / metabolism. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2007 Sep;57(3):534-5 [17707161.001]
  • (PMID = 17097363.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratolytic Agents; 0 / Proliferating Cell Nuclear Antigen; LCH760E9T7 / Acitretin
  •  go-up   go-down


19. Itoh Y, Ninomiya Y, Henta T, Tajima S, Ishibashi A: Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses. J Dermatol; 2000 Aug;27(8):513-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses.
  • Based on the opinion that 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) may be disadvantageous to Oriental patients with dark skin, including Japanese, because the competing chromophore melanin inhibits the photochemical reaction, we assessed the therapeutic effects when Japanese AK were treated with ALA-PDT.
  • However, a larger number of treatment sessions were required.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Arm. Asian Continental Ancestry Group / genetics. Facial Dermatoses / drug therapy. Facial Dermatoses / genetics. Female. Humans. Japan. Leg. Male. Neck. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10989575.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


20. Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC: Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Arch Dermatol; 2010 Dec;146(12):1438-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Carcinoma, Squamous Cell / chemically induced. Melanoma / drug therapy. Pyridines / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Drug Administration Routes. Follow-Up Studies. Humans. Leg. Male. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Receptors, Vascular Endothelial Growth Factor

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21173337.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / TL1RR024126
  • [Publication-type] Case Reports; Letter; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


21. Ly L, Czarnecki D: The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol; 2007 Nov;157(5):1076-8
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis.
  • [MeSH-major] Carcinoma, Squamous Cell / chemically induced. Immunoglobulin G / adverse effects. Immunosuppressive Agents / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Etanercept. Humans. Keratoacanthoma / chemically induced. Leg. Male. Middle Aged. Psoriasis / drug therapy. Receptors, Tumor Necrosis Factor / therapeutic use. Skin Diseases / chemically induced

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854370.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


22. Kossard S, Artemi P: Acitretin for hypertrophic lichen planus-like reaction in a burn scar. Arch Dermatol; 2000 May;136(5):591-4
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Acitretin / therapeutic use. Carcinoma, Squamous Cell / prevention & control. Cicatrix, Hypertrophic / complications. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Skin Neoplasms / prevention & control
  • [MeSH-minor] Biopsy. Burns / complications. Burns / pathology. Diagnosis, Differential. Humans. Leg. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10815851.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Keratolytic Agents; LCH760E9T7 / Acitretin
  •  go-up   go-down






Advertisement